Australia markets closed

Poxel S.A. (PXXLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.10000.0000 (0.00%)
At close: 11:17AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.1000
Open2.1000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.1000 - 2.1000
52-week range2.1000 - 9.2600
Volume500
Avg. volume5
Market cap52.68M
Beta (5Y monthly)1.62
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting

    LYON, France, June 22, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that it held its ordinary annual and extraordinary general meeting of shareholders on June 21, 2022. The meeting was held at Collège Hôtel, 5 Place Saint-Paul, 69005 LYON, and was chaired by Pierre

  • Business Wire

    Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041

    LYON, France, June 09, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that the U.S. Patent and Trademark Office (PTO) has issued to Poxel US Patent No. 11319313 which represents a new patent for PXL065, a novel, proprietary deuterium-stabilized R-stereoisomer of piogl

  • Business Wire

    Poxel Announces its Participation in Upcoming Investor and Scientific Conferences

    LYON, France, May 31, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that the Poxel team will participate in several upcoming investor and scientific conferences in June 2022.